The AWARD-11 study demonstrates that people with type 2 diabetes receiving a higher weekly dose of 3mg and/or 4.5mg instead of 0.75mg and 1.5mg administered by subcutaneous injections would see an improvement in blood glucose levels and weight loss.

https://www.gelbe-liste.de/diabetologie/dulaglutid-typ2-diabetes